Scientific work

Prof. Dr. Marıa Del Pılar Laguna Pes

491 publications. The source of the information is stated next to each publication.

Back to profile

  1. Analysis. J Urol. 2017 Feb;197(2):314-315.

    Source: medipol.com.tr profile page

  2. 330. D.A. Wollin, A.D. Joyce, M. Gupta, M.Y. Wong, M.P. Laguna Pes, S. Gravas, J. Gutierrez, L. Cormio, K. Wang, G.M. Preminger. Antibiotic use and the prevention and management of infectious complications in stone disease. World J Urol. 2017 Feb 3.

    Source: medipol.com.tr profile page

  3. 331. M.P. Laguna Pes. Re: Cost-Effectiveness of Management Options for Small Renal Mass: A Systematic Review. J Urol. 2017 Mar;197(3 Pt 1):602-603.

    Source: medipol.com.tr profile page

  4. 332. E.I.M.L. Liem, J. Baard, E.C.C. Cauberg, M.T.J. Bus, D.M. de Bruin, M.P. Laguna Pes, J.J.M.C.H. de la Rosette, Th.M. de Reijke. Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette-Guérin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer. Med Oncol. 2017 Sep 2;34(10):172.

    Source: medipol.com.tr profile page

  5. 333. M.J. Scheltema, A.W. Postema, D.M. de Bruin, M. Buijs, M.R. Engelbrecht, M.P. Laguna Pes, H. Wijkstra, Th.M. de Reijke, J.J.M.C.H. de la Rosette. Irreversible electroporation for the treatment of localized prostate cancer: a summary of imaging findings and treatment feedback. Diagn Interv Radiol. 2017 Sep-Oct;23(5):365-370.

    Source: medipol.com.tr profile page

  6. 334. M.P. Laguna Pes. Re: Irreversible Electroporation of Small Renal Masses: Suboptimal Oncologic Efficacy in an Early Series. J Urol. 2017 Sep;198(3):481-482.

    Source: medipol.com.tr profile page

  7. 335. M.P. Laguna Pes. Re: Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. J Urol. 2017 Sep;198(3):480-482.

    Source: medipol.com.tr profile page

  8. 336. M.P. Laguna Pes. Re: Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. J Urol. 2017 Jul;198(1):36-37.

    Source: medipol.com.tr profile page

  9. 337. M.P. Laguna Pes. Re: Robot-Assisted vs Open Adrenalectomy: Evaluation of Cost-Effectiveness and Peri-Operative Outcome. J Urol. 2017 Jun;197(6):1438.

    Source: medipol.com.tr profile page

  10. 338. M.P. Laguna Pes. Re: Oncologic Outcomes of Kidney-Sparing Surgery versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-Muscle Invasive Bladder Cancer Guidelines Panel. J Urol. 2017 Jun;197(6):1437-1438.

    Source: medipol.com.tr profile page

  11. 339. R.R. Pessoa, R. Autorino, M.P. Laguna Pes, W.R. Molina, D. Gustafson, L. Nogueira, da Silva, P.N. Werahera , F.J. Kim. Laparoscopic Versus Percutaneous Cryoablation of Small Renal Mass: Systematic Review and Cumulative Analysis of Comparative Studies. Clin Genitourin Cancer. 2017;15(5):513-519.

    Source: medipol.com.tr profile page

  12. 340. M.P. Laguna. Re: First-Line Sunitinib versus Pazopanib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma. Database Consortium. J Urol. 2017 Mar;197(3 Pt 1):603.

    Source: medipol.com.tr profile page

  13. 341. M.P. Laguna. Re: Urinary Collecting System Invasion is Associated with Poor Survival in Patients with Clear-Cell Renal Cell Carcinoma. J Urol. 2017 Nov;198(5):976-978.

    Source: medipol.com.tr profile page

  14. 342. M.P. Laguna. Re: Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness. J Urol. 2017 Nov;198(5):977-978.

    Source: medipol.com.tr profile page

  15. 343. M.P. Laguna. Re: Partial Nephrectomy versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-Analysis of Comparative Studies. J Urol. 2017 Dec;198(6):1204-1206.

    Source: medipol.com.tr profile page

  16. 344. M.P. Laguna. Re: Efficacy of Systemic Chemotherapy plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. J Urol. 2017 Dec;198(6):1205-1206.

    Source: medipol.com.tr profile page

  17. 345. M.P. Laguna. Re: Mortality, Morbidity and Healthcare Expenditures after Local Tumour Ablation or Partial Nephrectomy for T1A Kidney Cancer. J Urol. 2017 Aug;198(2):252-254

    Source: medipol.com.tr profile page

  18. 346. M.P. Laguna. Re: Findings and Impact of Early Imaging after Partial Nephrectomy. J Urol. 2017 Aug;198(2):253-254.

    Source: medipol.com.tr profile page

  19. 347. M.P. Laguna. Re: End-Stage Renal Disease after Renal Surgery in Patients with Normal Preoperative Kidney Function: Balancing Surgical Strategy and Individual Disorders at Baseline. J Urol. 2017 May;197(5):1214-1215.

    Source: medipol.com.tr profile page

  20. 348. M.P. Laguna. Re: Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. J Urol. 2017 May;197(5):1215.

    Source: medipol.com.tr profile page

  21. 349. J.L Boormans, J. Mayor de Castro, L. Marconi, Y. Yuan, M.P. Laguna Pes, C. Bokemeyer, N. Nicolai, F. Algaba, J. Oldenburg, P. Albers. Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel. Eur Urol. 2017 Nov 20. pii: S0302-2838(17)30826-6

    Source: medipol.com.tr profile page

  22. 350. M.P. Laguna. Re: A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. J Urol. 2018 Jan;199(1):23-25.

    Source: medipol.com.tr profile page

  23. 351. M.P. Laguna. Re: Surgical Histopathology for Suspected Oncocytoma on Renal Mass Biopsy: A Systematic Review and Meta-Analysis. J Urol. 2018 Jan;199(1):24-25.

    Source: medipol.com.tr profile page

  24. 352. M.P. Laguna. Re: The Impact of Quality Variations on Patients Undergoing Surgery for Renal Cell Carcinoma: A National Cancer Database Study. J Urol. 2018 Feb;199(2):338-339.

    Source: medipol.com.tr profile page

  25. 353. M.P. Laguna. Re: When to Perform Preoperative Chest Computed Tomography for Renal Cancer Staging. J Urol. 2018 Feb;199(2):339.

    Source: medipol.com.tr profile page

  26. 356. A.Basiri, J.J. de la Rosette, S. Tabatabaei, H.H. Woo, M.P. Laguna, H. Shemshaki.Comparison of retropubic, laparoscopic and robotic radical prostatectomy: who is the winner? World J Urol. 2018 Apr;36(4):609-621.

    Source: medipol.com.tr profile page

  27. 357. M.P. Laguna. Re: Stereotactic Ablative Body Radiotherapy for Inoperable Primary Kidney Cancer: A Prospective Clinical Trial. J Urol. 2018 Jun;199(6):1393-1394.

    Source: medipol.com.tr profile page

  28. 358. M.P. Laguna. Re: Randomized Phase III Trial of Adjuvant Pazopanib versus Placebo after Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma. J Urol. 2018 Jun;199(6):1393-1394.

    Source: medipol.com.tr profile page

  29. 359. M.P. Laguna. Re: Stereotactic Ablative Body Radiotherapy for Inoperable Primary Kidney Cancer: A Prospective Clinical Trial. J Urol. 2018 Jun;199(6):1393-1394.

    Source: medipol.com.tr profile page

  30. 360. M.P. Laguna. Re: Randomized Phase III Trial of Adjuvant Pazopanib versus Placebo after Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma. J Urol. 2018 Jun;199(6):1393-1394.

    Source: medipol.com.tr profile page

  31. 361. M.P. Laguna. Re: Recommendations for the Management of Rare Kidney Cancers. J Urol. 2018 May;199(5):1109.

    Source: medipol.com.tr profile page

  32. 362. M.P. Laguna. Re: Intravenous Mannitol versus Placebo during Partial Nephrectomy in Patients with Normal Kidney Function: A Double-Blind, Clinically-Integrated, Randomized Trial. J Urol. 2018 May;199(5):1108-1109.

    Source: medipol.com.tr profile page

  33. 363. M.P. Laguna. Re: Defining the Role of Intraoperative Transesophageal Echocardiography during Radical Nephrectomy with Inferior Vena Cava Tumor Thrombectomy for Renal Cell Carcinoma. J Urol. 2018 Apr;199(4):890.

    Source: medipol.com.tr profile page

  34. 364. M.P. Laguna. Re: Impact of Diagnostic Ureteroscopy on Intravesical Recurrence in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Cancer: A Systematic Review and Meta-Analysis. J Urol. 2018 Apr;199(4):889-890.

    Source: medipol.com.tr profile page

  35. 366. M.P. Laguna. Re: Pathological Heterogeneity in Sporadic Synchronous RenalTumors: Is the Histological Concordance Predictable? J Urol. 2018 Oct;200(4):694-695.

    Source: medipol.com.tr profile page

  36. 367. M.P. Laguna. Re: Incidence of T3a Up-Staging and Survival after Partial Nephrectomy: Size-Stratified Rates and Implications for Prognosis. J Urol. 2018 Oct;200(4):695.

    Source: medipol.com.tr profile page

  37. 368. L. Sandbergen, S. Guven, M.P. Laguna. Can ablation win against partial nephrectomy and become first line therapy in cT1a renal tumours? Curr Opin Urol. 2019 Jan;29(1):70-77.

    Source: medipol.com.tr profile page

  38. 369. M.P. Laguna. Re: A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma. J Urol. 2018 Nov;200(5):941-942.

    Source: medipol.com.tr profile page

  39. 370. M.P. Laguna. Re: Patients' Preferences for Adjuvant Sorafenib after Resection of Renal Cell Carcinoma in the SORCE Trial: What Makes it Worthwhile? J Urol. 2018 Sep;200(3): 494-496.

    Source: medipol.com.tr profile page

  40. 371. M.P. Laguna. Re: Perioperative Morbidity of Lymph Node Dissection for Renal Cell Carcinoma: A Propensity Score-Based Analysis. J Urol. 2018 Sep;200(3):495-496.

    Source: medipol.com.tr profile page

  41. 372. M.P. Laguna. Re: The Role of Lymph Node Dissection in the Management of Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. J Urol. 2019 Jan;201(1):26-27.

    Source: medipol.com.tr profile page

  42. 373. M.P. Laguna. Re: Oncologic Outcomes of Patients with Positive Surgical Margin after Partial Nephrectomy: A 25-Year Single Institution Experience. J Urol. 2019 Jan; 201(1) :27-28

    Source: medipol.com.tr profile page

  43. 374. M.P. Laguna. Re: Outcomes of Pathologic Stage T3a Renal Cell Carcinoma Up-Staged from Small Renal Tumor: . J Urol. 2019 Feb;201(2):224-225

    Source: medipol.com.tr profile page

  44. 375. M.P. Laguna. Re: Molecular Subtypes of Clear-Cell Renal Cell Carcinoma Are Prognostic for Outcome after Complete Metastasectomy. J Urol. 2019 Apr;201(4):664-665

    Source: medipol.com.tr profile page

  45. 377. T. Deng, Y. Chen, B. Liu, M.P. Laguna, J.J.M.C.H. de la Rosette, X. Duan, W. Wu, G. Zeng. systematic review and cumulative analysis of the managements for proximal impacted ureteral stones. World J Urol. 2019 Aug;37(8):1687-1701

    Source: medipol.com.tr profile page

  46. 378. M.P. Laguna. Re: The Probability of Aggressive versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment. J Urol. 2019 May;201(5):856

    Source: medipol.com.tr profile page

  47. 379. M.P. Laguna. Re: Time Trends in Service Provision and Survival Outcomes for Patients with Renal Cancer Treated by Nephrectomy in England 2000-2010. J Urol. 2019 May;201(5):855

    Source: medipol.com.tr profile page

  48. 380. M.P. Laguna. Re: Comparative Effectiveness of Management Options for Patients with Small Renal Masses: . J Urol. 2019 Mar;201(3):439

    Source: medipol.com.tr profile page

  49. 381. M.P. Laguna. Re: Active Surveillance for Localized Renal Masses: . J Urol. 2019 Mar;201(3):440.

    Source: medipol.com.tr profile page

  50. 382. M.P. Laguna. Re: Adjuvant Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. J Urol. 2019 Jun;201(6):1050-1051

    Source: medipol.com.tr profile page